Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Biologic therapy for rheumatoid arthritis.

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology.

Progress in treatment for Crohn's disease.

Infliximab for Crohn's disease: more questions than answers.

Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease.

Progress in the treatment of rheumatoid arthritis.

Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor.

Tuberculosis and treatment with infliximab.

Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Abdominal tuberculosis in urban Britain--a common disease.

The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis.

Extraintestinal manifestations of idiopathic inflammatory bowel disease.

Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

Biological insights from clinical trials with anti-TNF therapy.

Infliximab (Remicade) for Crohn's disease.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Cytokine/chemokine cascades in immunity to tuberculosis.

Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.